Consumer medicine information

DuoTrav Eye Drops

Travoprost; Timolol

BRAND INFORMATION

Brand name

DuoTrav

Active ingredient

Travoprost; Timolol

Schedule

S4

 

Consumer medicine information (CMI) leaflet

Please read this leaflet carefully before you start using DuoTrav Eye Drops.

What is in this Leaflet

Read this leaflet carefully before you start to use DuoTrav Eye Drops.

This leaflet answers some common questions about DuoTrav Eye Drops. It does not contain all the available information. It does not take the place of talking to your doctor or pharmacist.

The information in this leaflet was last updated on the date listed on the final page. More recent information on the medicine may be available.

You should ensure that you speak to your pharmacist or doctor to obtain the most up to date information on the medicine.

You can also download the most up to date leaflet in Australia from www.novartis.com.au and www.medsafe.govt.nz in New Zealand. The updates may contain important information about the medicine and its use of which you should be aware.

All medicines have risks and benefits. Your doctor has weighed the risks of you using DuoTrav against the benefits they expect it will have for you.

If you have any concerns about using this medicine, ask your doctor or pharmacist.

Keep this leaflet with your medicine. You may need to read it again.

What DUOTRAV is used for

DuoTrav Eye Drops are used to lower pressure in the eye and to treat glaucoma. Glaucoma is a condition in which the pressure of the fluid in the eye may be high. However, some people with glaucoma may have normal eye pressure. Also, some people with raised eye pressure may not have glaucoma.

DuoTrav Eye Drops contain two active ingredients, travoprost and timolol, that lower the pressure in the eye. Travoprost belongs to a family of medicines known as 'prostaglandins'. Timolol belongs to a family of medicines known as 'beta-blockers'.

DuoTrav Eye Drops lower the pressure within the eye by two processes. They improve the flow of fluid from your eye(s) (travoprost) and decrease the production of fluid (timolol). Although DuoTrav Eye Drops help to control your glaucoma they do not cure it.

Before prescribing DuoTrav Eye Drops for you, your doctor will have examined the eye and decided that DuoTrav Eye Drops is the right medicine.

Your doctor may have prescribed DuoTrav Eye Drops for another reason. Ask your doctor if you have any questions about why DuoTrav Eye Drops have been prescribed for you.

DuoTrav Eye Drops are not addictive.

For more information about glaucoma contact Glaucoma Australia on 1800 500 880 or Glaucoma NZ on 0800 GLAUCOMA or 0800 452 826.

Use in children

This medicine is not recommended in children.

The safety and effectiveness of Duotrav Eye Drops has not been established in children.

Before you use DuoTrav

When you must not use it

Do not use DuoTrav Eye Drops if you have an allergy to:

  • DuoTrav Eye Drops, travoprost, timolol or any of the ingredients listed at the end of this leaflet
  • any other 'prostaglandin' or 'beta-blocker' medicine.

Some of the symptoms of an allergic reaction may include:

  • shortness of breath
  • wheezing or difficulty breathing
  • swelling of the face, lips, tongue or other parts of the body
  • rash, itching or hives on the skin.

Do not use DuoTrav Eye Drops if:

  • you are a pregnant woman or intend to become pregnant.
    DuoTrav Eye Drops are not recommended in pregnancy.
  • you have asthma, or a history of asthma, chronic obstructive lung disease (emphysema), or other breathing problems
  • you have certain heart conditions, such as a very slow heart rate, an irregular heart beat or heart failure.

Do not use this medicine if:

  • the foil overwrap pouch appears damaged in any way (it is possible that the foil overwrap pouch may have been removed by your pharmacist)
  • the bottle/packaging shows signs of tampering
  • the expiry date on the bottle/carton has passed. If you use this medicine after the expiry date has passed, it may not work as well.
    If it has expired or is damaged, return it to your pharmacist for disposal.

Do not use DuoTrav Eye Drops if you are wearing contact lenses. You can put your contact lenses into your eyes 15 minutes after you have used DuoTrav Eye Drops.

If you are not sure whether you should start using DuoTrav Eye Drops, talk to your doctor.

Before you start to use it

Tell your doctor if:

You have an allergy to any other medicines or any other substances, such as foods, preservatives or dyes.

You have a history of allergic problems, including eczema, hives or hay fever.

You are breastfeeding or intend to breastfeed. Your doctor will discuss the possible risks and benefits of using DuoTrav Eye Drops when breastfeeding.

You have or have had any of the following medical conditions:

  • heart disease
  • lung disease
  • circulation disorders such as Raynaud's disease
  • any other types of glaucoma
  • diabetes
  • myasthenia gravis
  • hyperthyroidism
  • dry eyes or any disease of the cornea.

Tell your doctor if you have any other medical conditions.

Tell your doctor if you are already using another beta-blocker eye drop and/or another prostaglandin eye drop. The use of two beta-blocker eye drops and/or prostaglandin eye drops at the same time is not recommended.

If you have not told your doctor about any of the above, tell them before you use DuoTrav Eye Drops.

Using or taking other medicines

Tell your doctor or pharmacist if you are using or taking any other medicines, including any that you buy without a prescription from a pharmacy, supermarket or health food shop.

Some medicines and DuoTrav Eye Drops may interfere with each other. These include:

  • certain medicines used to treat high blood pressure or heart conditions, including beta-blockers, calcium channel blockers or digoxin
  • certain medicines used to treat irregular heartbeats such as amiodarone and quinidine
  • medicines used to treat major depression such as fluoxetine or paroxetine
  • monoamine oxidase inhibitors (MAOIs) used to treat depression
  • narcotics, such as morphine, used to treat moderate to severe pain
  • medicines used to treat diabetes or high blood sugar
  • adrenaline used to treat anaphylactic shock (a severe, life threatening, hypersensitivity reaction)
  • other eye drops that contain a beta-blocker or a prostaglandin. This is particularly important if you are currently taking any tablets to treat glaucoma or you are using any other type of eye drops.

Some medicines may be affected by DuoTrav Eye Drops, or may affect how well it works. You may need different amounts of your medicines, or you may need to take different medicines.

Your doctor or pharmacist has more information on medicines to be careful with or avoid while using DuoTrav Eye Drops.

How to use DuoTrav

Carefully follow all directions given to you by your doctor and pharmacist. They may differ from the information contained in this leaflet.

If you are being changed from one eye drop to another, follow your doctor's instructions carefully as to when to stop the old drops and when to start the new drops.

If you do not understand the instructions on the carton, ask your doctor or pharmacist for help.

How much to use

The usual dose is one drop of DuoTrav Eye Drops once daily at about the same time each day, in either one or both eyes.

Follow all directions given to you by your doctor carefully. They may differ from the information contained in this leaflet.

These dosing instructions will be printed on the label your pharmacist puts on the bottle or carton.

How to use it

It is important to use DuoTrav Eye Drops exactly as your doctor or pharmacist has told you. If you use it less often than you should, it may not work as well and the eye problem may not improve. Using it more often than you should may not improve the eye problem any faster and may cause increased side effects.

If you are wearing contact lenses, remove them before putting the drops in your eye.

Follow these steps to use DuoTrav Eye Drops:

  1. Wash your hands well with soap and water.
  2. Immediately before using a bottle for the first time, tear open the foil overwrap pouch (if present) and take the bottle out (see Diagram 1).

  1. Remove the cap from the bottle.
  2. Hold the bottle upside down in one hand between your thumb and first (index) finger. It will not leak (see Diagram 2).

  1. Using your other hand, gently pull down your lower eyelid to form a pouch.
  2. Tilt your head back and look up.
  3. Place the tip of the bottle close to your lower eyelid. Do not let it touch your eye.
  4. Release one drop into the pouch formed between your eye and eyelid by gently squeezing the bottle (see Diagram 3).

  1. Close your eye and keep it closed. Do not blink or rub your eye.
  2. With the eye closed, place your index finger against the inside corner of your eye and press against your nose for a couple of minutes. This will help to stop the medicine from draining through the tear duct to the nose and throat, from where it can be absorbed into other parts of your body. This will also reduce the unpleasant taste sensation that some people experience when using these drops.
  3. If necessary, repeat the above steps for your other eye.
  4. Your eyelids can only hold less than one drop at a time, so it is normal for a small amount of the eye drop to spill onto your cheek. You should wipe away any spillage with a tissue.
  5. Replace the cap on the bottle, closing it tightly.
  6. Wash your hands again with soap and water to remove any residue.

Wait at least 15 minutes before inserting your contact lenses.

You may feel a slight burning sensation in the eye shortly after using the eye drops. If this persists, or is very uncomfortable, contact your doctor or pharmacist.

Be careful not to touch the dropper tip against your eye, eyelid or anything else to avoid contaminating the eye drops. Contaminated eye drops may give you an eye infection.

If you have trouble knowing whether you have placed your drops correctly, you may want to store them in the fridge. Some people find it easier to feel the drops in the eye if they are cold.

After using DuoTrav Eye Drops, wait at least 5 minutes before putting any other eye drops in your eye(s).

When to use it

Use DuoTrav Eye Drops once a day, at about the same time each day, unless your doctor tells you otherwise. Using your eye drops at the same time each day will have the best effect on your eye pressure. It will also help you remember when to use the eye drops.

How long to use it

Your doctor or pharmacist will tell you how long to use DuoTrav Eye Drops.

DuoTrav Eye Drops help control your condition but do not cure it. Therefore, DuoTrav Eye Drops must be used every day. Continue using DuoTrav Eye Drops for as long as your doctor prescribes.

Do not use DuoTrav Eye Drops longer than your doctor tells you. If you use DuoTrav Eye Drops longer than your doctor or pharmacist tells you, the chance of side effects may increase.

If you are unsure about when or how to stop using DuoTrav Eye Drops, you should talk to your doctor or pharmacist.

If you forget to use it

If you forget to use DuoTrav Eye Drops, you should put the drops that you missed in the eye(s) as soon as you remember and then go back to using them as recommended by your doctor. If it is almost time for the next dose, skip the dose that you missed and continue using them as recommended.

If you are not sure whether to skip the dose, talk to your doctor or pharmacist.

Do not use a double dose to make up for the dose that you missed. Using multiple doses may cause unwanted side effects.

If you have trouble remembering to use your eye drops, ask your pharmacist for some hints.

If you use too much (overdose)

If you accidentally put several drops in your eye(s), immediately rinse your eye(s) with warm water.

If you think that you or someone else has swallowed any or all of the contents of DuoTrav Eye Drops or used too many drops, immediately telephone your doctor or the Poisons Information Centre on 13 11 26 in Australia or the National Poisons Centre in New Zealand on 0080 POISON or 800 764 766 for advice. Alternatively, go to Accident and Emergency at your nearest hospital. Do this even if there are no signs of discomfort or poisoning.

If DuoTrav Eye Drops are accidentally swallowed, or if you use too many drops, you may feel light-headed or dizzy, you may faint, have a very slow pulse rate, or have wheezing or difficulty breathing. Other effects include nausea, abdominal pain, fatigue, hot flushes and sweating.

While you are using DuoTrav

Things you must do

Tell all doctors and pharmacists who are treating you are using DuoTrav Eye Drops.

Tell your doctor if, for any reason, you have not used DuoTrav Eye Drops exactly as prescribed. Otherwise, your doctor may think that it was not effective and change the treatment unnecessarily.

You should have your eye pressure checked when your specialist says, to make sure DuoTrav Eye Drops are working.

If you develop an eye infection, receive an eye injury, or have eye surgery, tell your doctor. Your doctor may tell you to use a new bottle of DuoTrav Eye Drops because of possible contamination of the old one or may advise you to stop treatment with DuoTrav Eye Drops.

If you become pregnant while using DuoTrav Eye Drops, tell your doctor immediately.

If you are about to be started on any new medicine, tell your doctor and pharmacist that you are using DuoTrav Eye Drops.

Things you must not do

Do not:

  • let children handle DuoTrav Eye Drops
  • stop using DuoTrav Eye Drops without first asking your doctor
  • give this medicine to anyone else, even if they appear to have the same condition as you
  • use DuoTrav Eye Drops to treat other complaints unless your doctor or pharmacist tells you to.

Things to be careful of

Be careful driving or operating machinery until you know how DuoTrav Eye Drops affect you and your vision. This medicine may cause temporary blurred vision or other visual disturbances which may affect the ability to drive or use machinery in some people.

If blurred vision occurs when you use your drops, wait until your vision is clear before driving or operating machinery.

Side effects

Tell your doctor or pharmacist as soon as possible if you do not feel well while you are using DuoTrav Eye Drops.

DuoTrav Eye Drops help most people with elevated eye pressure and glaucoma, but it may have unwanted side effects in a few people.

All medicines can have side effects. Sometimes they are serious, most of the time they are not. You may need medical treatment if you get some of the side effects.

Do not be alarmed by the following list of possible side effects. You may not experience any of them. Ask your doctor or pharmacist to answer any questions you may have.

Tell your doctor if you notice any of the following effects in the eye(s) and the eye area and they worry you. These are usually the most common side effects of your medication. They are usually mild and short-lived:

  • redness of eye
  • eye pain
  • eye discomfort
  • alterations in vision, blurred vision or temporary reduction of vision
  • dry eyes
  • itchy eyes
  • eye surface inflammation with surface damage
  • eye irritation

You may also experience red, itching, swollen, heavy, painful or irritated eyelids, bleeding, crusty eyelids, inflammation of the eye, sensitivity to light, blurred vision, tired eyes, tearing, corneal erosion, swelling of the eye, double vision, drooping eyelid(s), sunken eyes (eyes appear more inset) and abnormal growth of eyelashes.

DuoTrav Eye Drops may gradually change the colour of the eye; this is due to an increase in pigment within the iris (coloured portion of the eye). This change in eye colour is most frequently seen in eyes with mixed colours (e.g. blue-brown, grey-brown); however, it may also occur with single coloured eyes. This change in eye colour may be permanent.

DuoTrav Eye Drops may cause changes to your eyelashes such as increased length, thickness and colour.

You may also experience reactions in other areas of your body, including:

  • headache
  • a change in blood pressure or heart rate
  • skin discolouration (including around the eye)
  • abnormal hair growth
  • loss of hair
  • tiredness
  • nervousness
  • seeing, feeling or hearing things that are not there (hallucination)
  • depression
  • numbness
  • loss of movement or coordination
  • muscular weakness
  • confusion or loss of memory
  • chest pain
  • cough
  • asthma
  • hoarse or strained voice
  • throat irritation
  • abnormal taste sensation.

Tell your doctor immediately or go to Accident and Emergency at your nearest hospital if you notice any of the following:

  • fast or irregular heartbeats, also called palpitations
  • dizziness and light-headedness, which may be due to low blood pressure
  • skin rash, itching
  • swelling of the hands, feet, ankles or legs.

These may be serious side effects. You may need urgent medical attention.

Serious side effects are rare.

If any of the following happen, stop using DuoTrav Eye Drops and tell your doctor immediately or go to Accident and Emergency at your nearest hospital:

  • wheezing, difficulty in breathing
  • shortness of breath
  • skin rash
  • very slow pulse, chest pain
  • fainting
  • swelling of the face, lips, mouth, tongue or throat which may cause difficulty in breathing or swallowing
  • severe and sudden onset of pinkish, itchy swellings on the skin, also called hives or nettle rash.

These hypersensitivity reactions can be very serious side effects. You may need urgent medical attention or hospitalisation. These side effects are very rare.

Other side effects not listed may also occur in some patients. Tell your doctor if you notice any other effects.

After using DuoTrav

Storage

Store DuoTrav Eye Drops in a cool, dry place where the temperature stays below 25°C. It is not necessary to store DuoTrav Eye Drops in the refrigerator, but it is acceptable if you prefer to instil cold drops.

Do not freeze.

Do not leave DuoTrav Eye Drops in the car, in the bathroom or in other warm, damp places. Heat and temperature can destroy some medicines.

Do not leave the top off the bottle for any length of time, to avoid contaminating the eye drops.

Keep DuoTrav Eye Drops, and all other medicines, in a safe place away from children. A locked cupboard at least one and a half metres above the ground is a good place to store medicines.

Disposal

Write the date on the bottle when you open the eye drops and throw out any remaining solution after four weeks. Eye drops contain a preservative which helps prevent germs growing in the solution for the first four weeks after opening the bottle. After this time, there is a greater risk that the drops may become contaminated and cause an eye infection. A new bottle should be opened.

If your doctor tells you to stop using the eye drops or the expiry date has passed, ask your pharmacist what to do with any remaining solution.

Product description

What it looks like

DuoTrav Eye Drops is a sterile, isotonic aqueous solution that comes in an oval dropper bottle with a screw cap containing 2.5 mL of eye drop solution. The bottle is covered in a foil overwrap pouch, although this may have been removed by your pharmacist.

Ingredients

DuoTrav Eye Drops contain the active ingredients:

  • travoprost 0.004%
  • timolol maleate, equivalent to timolol 0.5%.

DuoTrav Eye Drops also contain:

  • polyquaternium-1 (0.01 mg/mL) as preservative
  • castor oil - ethoxylated hydrogenated
  • boric acid
  • sodium chloride
  • propylene glycol
  • mannitol
  • water-purified.

The pH of the solution may be adjusted with sodium hydroxide and/or hydrochloric acid.

Supplier

This product is supplied in Australia by:

Novartis Pharmaceuticals Australia Pty Limited
ABN 18 004 244 160
54 Waterloo Road
Macquarie Park NSW 2113
Telephone No. 1800 671 203
www.novartis.com.au

This product is supplied in New Zealand by:

Novartis New Zealand Limited
PO Box 99102
Newmarket
Auckland 1149
New Zealand
Free Phone: 0800 354 335.

Australian Registration Number

AUST R: 177772

Date of Preparation

This leaflet was revised in November 2023.

© Novartis Pharmaceuticals Australia Pty Limited 2020

® Registered Trademark

Internal document code
(dut031123c) based on PI (dut031123i)

Published by MIMS December 2023

BRAND INFORMATION

Brand name

DuoTrav

Active ingredient

Travoprost; Timolol

Schedule

S4

 

1 Name of Medicine

Travoprost and timolol maleate.

2 Qualitative and Quantitative Composition

DuoTrav Eye Drops is a combination eye drop containing a topical prostaglandin analogue, travoprost and a topical beta-adrenergic receptor blocking agent, timolol maleate. Each mL of DuoTrav Eye Drops contains 40 micrograms (0.004%) travoprost and 5 mg (0.5%) timolol (as timolol maleate 6.83 mg).
It is a sterile, isotonic aqueous solution with a buffered pH of approximately 6.8 and an osmolality of approximately 290 mOsmol/kg. The product is benzalkonium chloride (BAK) free and uses polyquaternium-1 (Polyquad) as a preservative.
For the full list of excipients, see Section 6.1 List of Excipients.

3 Pharmaceutical Form

Eye drops, solution.
Colourless to light yellow aqueous solution.

4 Clinical Particulars

4.1 Therapeutic Indications

Reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension for whom single agent therapy provides insufficient intraocular pressure reduction.

4.2 Dose and Method of Administration

Recommended dosage for adults (including the elderly).

Instil one drop of DuoTrav Eye Drops once daily at about the same time each day in the conjunctival sac of the affected eye(s).
DuoTrav Eye Drops should not be given more than once daily because travoprost is most effective at this dosage. If there is inadequate response to DuoTrav Eye Drops, consideration should be given to using the individual agents with timolol dosed twice daily.
If more than one topical ophthalmic product is being used, the eye drop products should be administered at least five minutes apart.

Switching to therapy with DuoTrav eye drops.

When substituting another ophthalmic antiglaucoma agent with DuoTrav Eye Drops, discontinue the other agent and start the following day with DuoTrav Eye Drops.

4.3 Contraindications

DuoTrav Eye Drops are contraindicated in patients with a known hypersensitivity to travoprost, timolol or any of the excipients in DuoTrav (see Section 6.1 List of Excipients).
DuoTrav Eye Drops are also contraindicated in pregnant women or women attempting to become pregnant (see Section 4.6 Fertility, Pregnancy and Lactation, Use in pregnancy).
Reactive airway disease including bronchial asthma, a history of bronchial asthma, or severe chronic obstructive pulmonary disease.
Sinus bradycardia, sick sinus syndrome, including sinoatrial block, second or third degree atrioventricular block, overt cardiac failure or cardiogenic shock.

4.4 Special Warnings and Precautions for Use

Not for injection or oral ingestion.

Cardiovascular/ respiratory reaction.

Like other topically applied ophthalmic agents, DuoTrav may be absorbed systemically. Due to the beta-adrenergic component timolol, the same types of adverse reactions seen with systemic beta-blockers may occur, including aggravation of Prinzmetal angina, aggravation of severe peripheral and central circulatory disorders, bradycardia and hypotension.
In patients with cardiovascular diseases (e.g. coronary heart disease, Prinzmetal's angina and cardiac failure) and hypotension, therapy with beta-blockers should be critically assessed and therapy with other active substances should be considered. Patients with cardiovascular diseases should be monitored for signs of deterioration of these diseases and for adverse reactions.
Patients with severe peripheral circulatory disturbance/ disorders (i.e. severe forms of Raynaud's disease or Raynaud's syndrome) should be treated with caution.
Respiratory and cardiac reactions, including death due to bronchospasm in patients with asthma and rarely death associated with cardiac failure have been reported following administration of timolol. Cardiac failure should be adequately controlled before treatment.

Anaphylactic reactions.

While taking beta-blockers, patients with a history of atopy or a history of severe anaphylactic reaction to a variety of allergens may be more reactive to repeated challenge with such allergens, whether accidental, diagnostic or therapeutic. In addition, such patients may be unresponsive to the usual doses of adrenaline used to treat anaphylactic reactions.

Concomitant therapy.

Timolol may react with other drugs (see Section 4.5 Interactions with Other Medicines and Other Forms of Interactions). The effect on IOP or the known effects of systemic beta-blockade may be exaggerated when DuoTrav Eye Drops is given to patients already receiving an oral beta-blocking agent. The response of these patients should be closely monitored. The use of two topical beta-blockers or topical prostaglandins is not recommended.
The use of DuoTrav Eye Drops may be considered in patients who require both timolol and travoprost, but it is unknown whether patients who are adequately controlled with timolol given twice daily plus travoprost given once daily will be as well controlled with DuoTrav Eye Drops given once daily. DuoTrav Eye Drops should not be used to initiate therapy.

Additional effects of beta-blockade.

Beta-blockers should be administered with caution in patients subject to spontaneous hypoglycaemia or to diabetic patients (especially those with labile diabetes) who are receiving insulin or oral hypoglycaemic agents. Beta-blockers may mask the signs and symptoms of acute hypoglycaemia.
Therapy with beta-blockers may mask certain symptoms of hyperthyroidism and abrupt withdrawal of therapy may precipitate a worsening of symptoms.
Therapy with beta-blockers may aggravate symptoms of myasthenia gravis.

Surgical anaesthesia.

Beta-blocking ophthalmological preparations may block systemic beta-agonist effects, e.g. of adrenaline. The anaesthesiologist should be informed when the patients is receiving timolol.

Ocular effects.

Travoprost may gradually change the eye colour by increasing the number of melanosomes (pigment granules) in melanocytes. Before treatment is instituted patients must be informed of the possibility of these changes. Unilateral treatment can result in permanent heterochromia. The long-term effects on the melanocytes and any consequences thereof are currently unknown. The change in iris colour occurs slowly and may not be noticeable for months to years. It may be permanent. The change in eye colour has predominantly been seen in patients with mixed coloured irides, i.e. blue brown, grey brown, yellow brown and green brown; however, it has also been observed in patients with brown eyes. Typically, the brown pigmentation around the pupil spreads concentrically towards the periphery in affected eyes, but the entire iris or parts of it may become more brownish. After discontinuation of therapy, no further increase in brown iris pigment has been observed.
Periorbital and/or eyelid skin darkening and deepening of the eyelid sulcus have been reported in association with the use of travoprost.
Eyelash changes occurred in over a third of patients treated with DuoTrav Eye Drops. These changes include: increased length, thickness, pigmentation and/or number of lashes.
There is no experience of DuoTrav Eye Drops in inflammatory ocular conditions, inflammatory, neovascular, angle closure or congenital glaucoma and only limited experience in open angle glaucoma of pseudophakic patients and in pigmentary glaucoma.
Although not reported during pivotal clinical trials with DuoTrav Eye Drops, macular oedema, including cystoid macular oedema, has been reported during treatment with prostaglandin F2α analogues. These reports have mainly occurred in aphakic patients, pseudophakic patients with a torn posterior lens capsule or anterior chamber lenses, or in patients with known risk factors for macular oedema. DuoTrav Eye Drops should be used with caution in these patients.
DuoTrav Eye Drops should be used with caution in patients with active intraocular inflammation, as well as patients with predisposing risk factors for uveitis.
Choroidal detachment has been reported with administration of aqueous suppressant therapy (e.g. timolol, acetazolamide) after filtration procedures.

Use of contact lens(es).

If patients continue to wear contact lenses while under treatment with DuoTrav Eye Drops they should remove their lens(es) prior to instilling DuoTrav Eye Drops in the affected eye(s) and should not insert their lens(es) until 15 minutes after instillation of the eye drops.

Actions the healthcare professional should take.

Systemic absorption can be minimised if patients are instructed to gently occlude the nasolacrimal ducts for two minutes immediately after instillation of the eye drop.

Use in hepatic and renal impairment.

No dosage alteration of DuoTrav Eye Drops is necessary in these patients.

Use in the elderly.

No overall differences in safety and effectiveness have been reported between elderly and other adult patients.

Paediatric use.

DuoTrav Eye Drops is not recommended for use in children. The safety and effectiveness in paediatric patients have not been established.

Effects on laboratory tests.

No data available.

4.5 Interactions with Other Medicines and Other Forms of Interactions

No pharmacokinetic interactions were observed between travoprost and timolol following topical ocular administration of DuoTrav Eye Drops. No specific interaction studies were performed with DuoTrav Eye Drops and other drugs.

Travoprost.

The plasma protein binding of the active free acid form of travoprost is moderate (approximately 80%) and, therefore, drug-drug interactions involving protein binding are unlikely.

Timolol.

The potential exists for additive effects resulting in hypotension and/or marked bradycardia when timolol ophthalmic drops are administered with oral calcium channel blockers, catecholamine depleting drugs or β-adrenergic blocking agents, antiarrhythmics (including amiodarone and quinidine), digitalis glycosides, parasympathomimetics, narcotics and monoamine oxidase inhibitors (MAOIs).
Potentiated systemic beta-blockade (e.g. decreased heart rate, depression) has been reported during combined treatment with CYP2D6 inhibitors (e.g. quinidine, fluoxetine, paroxetine) and timolol.
Beta-blockers can decrease the response to adrenaline used to treat anaphylactic reactions.
Special caution should be exercised in patients with a history of atopy or anaphylaxis. (See Section 4.4 Special Warnings and Precautions for Use).
Although DuoTrav Eye Drops used alone has little or no effect on pupil size, mydriasis has occasionally been reported when timolol is given with adrenaline.
Beta-blockers may increase the hypoglycaemic effect of antidiabetic agents.

4.6 Fertility, Pregnancy and Lactation

Effects on fertility.

There are no human data on the effects of DuoTrav Eye Drops on male or female fertility.

Travoprost.

Travoprost had no effects on mating behaviour or fertility in male and female rats at subcutaneous doses up to 10 microgram/kg/day (equivalent to 54 times the human exposure at the MRHOD), although embryo-foetal resorption was increased at 10 microgram/kg/day (further information on effects on pregnancy is included under Section 4.6 Fertility, Pregnancy and Lactation, Use in pregnancy).

Timolol.

Timolol maleate alone had no effects on male or female fertility when administered at 300 microgram/kg/day, PO.
(Category C)
No adequate and well controlled studies have been performed in pregnant women. DuoTrav Eye Drops may interfere with the maintenance of pregnancy. It should not be used by women during pregnancy or by women attempting to become pregnant.

Travoprost.

The human dose of travoprost with the recommended dosage of DuoTrav Eye Drops is 2.2 microgram/day or 0.044 microgram/kg/day, with plasma concentrations of up to 0.020 nanogram/mL. Travoprost and/or its metabolites crossed the placenta in rats. Travoprost was teratogenic in rats at intravenous doses of 10 microgram/kg/day, equivalent to 98 times the human exposure; it increased the incidence of hydrocephaly and bone abnormalities (e.g. vertebral malformations). Travoprost was not teratogenic in rats at intravenous doses of up to 3 microgram/kg/day (29 times the human exposure). When administered to rats during organogenesis (gestation days 6 to 17), travoprost produced increases in postimplantation loss and early delivery at intravenous doses of 10 microgram/kg/day (98 times the human exposure). Postimplantation loss increased in rats at subcutaneous doses of 10 microgram/kg/day (54 times human exposure) administered from 2 weeks prior to mating to gestation day 7. Travoprost was not teratogenic in mice at subcutaneous doses of up to 0.3 microgram/kg/day; postimplantation loss and early delivery were increased in mice at subcutaneous doses of 1 microgram/kg/day (5.8 times the human exposure), but not at 0.3 microgram/kg/day (1.7 times the human exposure).
Travoprost Eye Drops 0.003% administered to rabbits during organogenesis appeared to increase incidence of foetal loss.
In rats administered travoprost from gestation day 7 to lactation day 21 by subcutaneous injection, abortions occurred at 0.72 microgram/kg/day (4 times human exposure), and decreased gestation length and increased stillbirths (also see Use in lactation) occurred at ≥ 0.12 microgram/kg/day (0.65 times human exposure).

Timolol.

Timolol maleate was not teratogenic in mice, rats and rabbits. Embryo-foetal development studies with timolol maleate in mice and rabbits showed no evidence of embryo-foetal toxicity at doses up to 50 mg/kg/day. At higher doses, increases in resorptions and foetal variations (14 ribs and hypoplastic sternebrae) were noted in mice (1,000 mg/kg/day) and increased resorption in rabbits (≥ 90 mg/kg/day). In rats, delayed ossification was seen at ≥ 50 mg/kg/day and a decreased number of caudal vertebral bodies and arches and an increase in hypoplastic sternebrae were noted at 500 mg/kg/day.
Epidemiological studies show a risk for intrauterine growth retardation when beta-blockers are administered by the oral route. In addition, signs and symptoms of beta-blockade (e.g. bradycardia, hypotension, respiratory distress and hypoglycaemia) have been observed in the neonate when systemic beta-blockers have been administered to the mother until delivery.
 Nursing women who use DuoTrav Eye Drops should use caution because of the potential for serious adverse reactions from DuoTrav Eye Drops in breastfeeding infants.

Travoprost.

There are no data on the excretion of travoprost into human milk or on the safety of travoprost exposure in infants. Because many drugs are excreted in human milk and adverse effects in rat pups were observed at low doses of travoprost (see below), nursing women who use DuoTrav Eye Drops should stop breastfeeding. A study in rats showed that travoprost and/or its metabolites were excreted in milk. Increased pup mortality and depressed pup growth and development occurred in rats where the dams were subcutaneously administered travoprost from gestation day 7 to lactation day 21 at greater than or equal to 0.12 microgram/kg/day, corresponding to 2.7 the expected human dose.

Timolol.

Timolol maleate has been detected in human milk following oral and ocular administration.

4.7 Effects on Ability to Drive and Use Machines

As with other ophthalmic medications, patients should be advised to exercise caution if they experience transient blurred vision following instillation of eye drops. Patients should wait until their vision clears before driving or using machinery.

4.8 Adverse Effects (Undesirable Effects)

DuoTrav (polyquad preserved).

Adverse events arising from clinical trials of 6 week to 12 month duration involving DuoTrav (Polyquad preserved) were consistent with the known safety profile for DuoTrav (BAK preserved).
In 3 clinical trials involved in the development of DuoTrav (Polyquad preserved), 372 patients/ subjects were exposed for up to 12 months. The most frequently reported treatment related undesirable effect with DuoTrav (Polyquad preserved) was hyperaemia of the eye (11.8%), which included ocular or conjunctival hyperaemia. The majority of patients (91%) who experienced hyperaemia of the eye did not discontinue therapy as a result of this reaction.
The following adverse reactions listed below were observed in clinical studies. They are ranked according to system organ class and classified according to the following convention: very common (≥ 1/10), common (≥ 1/100 to < 1/10), uncommon (≥ 1/1000 to < 1/100), rare (≥ 1/10,000 to < 1/1000), very rare (< 1/10,000), or not known (cannot be estimated from the available data). Within each frequency grouping, adverse reactions are presented in decreasing order of seriousness.
The following adverse reactions listed below were observed in the clinical studies.

Immune system disorders.

Uncommon: hypersensitivity.

Nervous system disorders.

Uncommon: headache.

Eye disorders.

Common: eye pain, ocular discomfort, dry eye, eye pruritus, ocular hyperaemia.
Uncommon: punctate keratitis, iritis, photophobia, vision blurred, conjunctivitis, meibomianitis, eyelid margin crusting, asthenopia, lacrimation increased, growth of eye lashes.

Cardiac disorders.

Uncommon: bradycardia.

Vascular disorders.

Uncommon: hypotension.

Skin and subcutaneous tissue disorders.

Uncommon: skin discolouration, hair growth abnormal (hypertrichosis).

General disorders and administration site conditions.

Uncommon: fatigue.

Investigations.

Uncommon: heart rate decreased.
Additional adverse reactions that have been seen with one of the active substances and may potentially occur with DuoTrav.

Travoprost.

Eye disorders.

Uveitis, conjunctival disorder, conjunctival follicles, iris hyperpigmentation.

Skin and subcutaneous tissue disorders.

Skin exfoliation.

Timolol.

Metabolism and nutrition disorders.

Hypoglycaemia.

Nervous system disorders.

Cerebral ischaemia, myasthenia gravis.

Eye disorders.

Diplopia.

Cardiac disorders.

Cardiac arrest, atrioventricular block, palpitations.

Respiratory, thoracic and mediastinal disorders.

Respiratory failure, nasal congestion.

Gastrointestinal disorders.

Diarrhoea, nausea.

General disorders and administration site conditions.

Asthenia.

Postmarketing experience.

Additional adverse reactions identified from post-marketing surveillance include the following. Frequencies cannot be estimated from the available data.

Nervous system disorders.

Dizziness.

Eye disorders.

Macular oedema, keratitis, blepharitis, conjunctivitis, erythema of eyelid, eye swelling, lacrimation increased, eyelid oedema, eyelid ptosis, eye irritation, lid sulcus deepened, iris hyperpigmentation.

Cardiac disorders.

Chest pain, palpitations.

Vascular disorders.

Hypertension.

Respiratory, thoracic and mediastinal disorders.

Dyspnoea, cough, asthma.

Skin and subcutaneous tissue disorders.

Rash, alopecia.

DuoTrav (BAK preserved).

The following adverse reactions listed below were observed in clinical studies with DuoTrav BAK-preserved formulation only. They are ranked according to system organ class and classified according to the following convention: very common (≥ 1/10), common (≥ 1/100 to < 1/10), uncommon (≥ 1/1000 to < 1/100), rare (≥ 1/10,000 to < 1/1000), very rare (< 1/10,000), or not known (cannot be estimated from the available data). Within each frequency grouping, adverse reactions are presented in decreasing order of seriousness.

Psychiatric disorders.

Common: nervousness.

Immune system disorders.

Uncommon: hypersensitivity.

Nervous system disorders.

Common: dizziness, headache.

Eye disorders.

Very common: ocular discomfort, ocular hyperaemia.
Common: punctate keratitis, anterior chamber inflammation, eye pain, photophobia, eye swelling, conjunctival haemorrhage, visual acuity reduced, visual disturbance, vision blurred, dry eye, eye pruritus, conjunctivitis, eye irritation, lacrimation increased, erythema of eyelid, blepharitis, asthenopia, growth of eyelashes.
Uncommon: keratitis, iritis, corneal erosion, eye allergy, conjunctival oedema, eyelid oedema.
Rare: trichiasis, distichiasis.

Cardiac disorders.

Common: arrhythmia, heart rate irregular, bradycardia (heart rate decreased).

Vascular disorders.

Common: hypertension, hypotension.

Respiratory, thoracic and mediastinal disorders.

Common: bronchospasm.
Uncommon: dyspnoea, cough, oropharyngeal pain, throat irritation, nasal discomfort, postnasal drip.
Rare: dysphonia.

Hepatobiliary disorders.

Uncommon: alanine aminotransferase increased, aspartate aminotransferase increased.

Skin and subcutaneous tissue disorders.

Common: urticaria, skin hyperpigmentation (periocular).
Uncommon: dermatitis contact, hypertrichosis, skin hyperpigmentation.
Rare: alopecia.

Musculoskeletal and connective tissue disorders.

Common: pain in extremity.

Renal and urinary disorders.

Uncommon: chromaturia.

General disorders and administration site conditions.

Uncommon: thirst.

Postmarketing experience.

Additional adverse reactions identified from postmarketing surveillance include the following. Frequencies cannot be estimated from the available data.

Nervous system disorders.

Cerebrovascular accident, syncope, paraesthesia.

Psychiatric disorders.

Hallucination, depression.

Eye disorders.

Corneal disorder.

Vascular disorders.

Oedema peripheral.

Gastrointestinal disorders.

Dysgeusia.

Reporting suspected adverse effects.

Reporting suspected adverse reactions after registration of the medicinal product is important. It allows continued monitoring of the benefit-risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions at www.tga.gov.au/reporting-problems.

4.9 Overdose

There are no human data available on overdosage with DuoTrav Eye Drops, although overdosage data are available on timolol, one of its individual active constituents.
If DuoTrav Eye Drops is accidentally ingested, the following information should be useful. One 2.5 mL bottle contains travoprost 0.1 mg and timolol 12.5 mg. Both timolol and travoprost are extensively metabolised in the liver.

Travoprost.

A single dose intravenous study in rats was conducted to elucidate maximal acute hazard. The dose employed was 250,000 times the proposed daily clinical exposure and over 5,000 times the possible exposure from the entire contents of one product container. No treatment related pharmacotoxic signs were present in the animals receiving travoprost.

Timolol.

Symptoms of systemic timolol overdosage are bradycardia, hypotension, bronchospasm and cardiac arrest. If such symptoms occur, treatment should be symptomatic and supportive. Studies have shown that timolol is not readily dialysable.
If overdosage with DuoTrav Eye Drops occurs, treatment should be symptomatic.
A topical overdose of DuoTrav Eye Drops may be flushed from the eyes with warm tap water.
For information on the management of overdose, contact the Poisons Information Centre on 13 11 26 (Australia).

5 Pharmacological Properties

5.1 Pharmacodynamic Properties

Mechanism of action.

DuoTrav Eye Drops contains two active components, travoprost and timolol, which lower intraocular pressure (IOP) by complementary mechanisms of action. Following the administration of DuoTrav Eye Drops, the reduction in IOP starts within 30 minutes and the maximum effect is reached after 12 hours. Significant IOP reduction is maintained for at least 24 hours after multiple treatments.
Glaucoma is defined as an optic neuropathy resulting in optic nerve head damage and visual field loss. The pathogenesis of glaucoma is multifactorial; the primary risk factors, however, are considered to be sustained elevated IOP and poor ocular perfusion. Clinical studies have shown that DuoTrav Eye Drops results in additional IOP reduction compared to either component administered alone and that the IOP lowering effect is comparable to Travatan Eye Drops (travoprost 0.004%) and timolol 0.5% administered concomitantly once daily.

Travoprost.

Travoprost is an ester prodrug of a PGF2α analogue and is hydrolysed to the active acid. The free acid is a prostaglandin FP receptor agonist. PGF2α analogues are believed to reduce the intraocular pressure (IOP) by increasing the outflow of aqueous humour via trabecular meshwork and uveoscleral pathways. Reduction of IOP in man starts about 2 hours after administration and maximum effect is reached after twelve hours. Pressure reduction is maintained for at least twenty four hours. Pivotal clinical studies have demonstrated that Travatan Eye Drops is effective as monotherapy at reducing IOP. Repeated observations over a period of one year indicate that the IOP lowering effect of travoprost is well maintained. In addition, travoprost slightly, but significantly, increased optic nerve head blood flow in a single study in rabbits.

Timolol.

Timolol maleate is a nonselective β1 and β2-adrenergic receptor blocking agent that does not have significant intrinsic sympathomimetic, direct myocardial depressant or local anaesthetic (membrane stabilising) activity. Timolol lowers IOP by decreasing the formation of aqueous humour in the ciliary epithelium. The precise mechanism of action is not clearly established.

Clinical trials.

Clinical studies with DuoTrav eye drops (polyquad preserved, BAK free).

Pharmacokinetics.

A double blind, two way crossover pharmacokinetic study (n = 24) was conducted comparing DuoTrav Eye Drops preserved with Polyquad (BAK free) or preserved with benzalkonium chloride (BAK). Patients were dosed in the morning for 5 days to evaluate the steady state plasma pharmacokinetics of travoprost (travoprost free acid (AL-5848)) and timolol. Plasma concentrations were below the limit of quantitation (LOQ = 0.0100 microgram/mL) in 94% of samples. Tmax and t1/2 were similar for timolol.

Efficacy studies.

A randomised double blind clinical equivalence study (n = 388) was conducted to compare DuoTrav (BAK free) against DuoTrav (BAK). Patients with open angle glaucoma or ocular hypertension were dosed once daily in the morning for 6 weeks. The primary efficacy parameter was mean IOP at the 9 am, 11 am and 4 pm time points at week 6. The percentage of patients with IOP < 18 mmHg or IOP percent reduction of ≥ 30% was a secondary variable.
DuoTrav Eye Drops (BAK free) and DuoTrav Eye Drops (BAK) produced statistically equivalent IOP lowering efficacy. Mean IOP reductions from baseline for both formulations were clinically relevant and statistically significant at all measurement times. Mean IOP reductions ranged from 7.5 to 8.3 mmHg for DuoTrav Eye Drops (BAK free) and from 8.1 to 8.5 mmHg for DuoTrav Eye Drops (BAK). Differences in mean IOP between DuoTrav Eye Drops (BAK free) and DuoTrav Eye Drops (BAK) ranged from 0.1 to 0.7 mmHg when evaluated across all on therapy visits and times (i.e. 3 diurnal times at 2 visits).
The percentage of patients with IOP < 18 mmHg or percent reduction ≥ 30% at each study visit ranged from 60% to 73% in the DuoTrav Eye Drops (BAK free) group and from 67% to 73% in the DuoTrav Eye Drops (BAK) group. The estimates of pooled IOP response in the two treatment groups were similar and not statistically significantly different (67% vs 70%, p = 0.3710). No clinically relevant safety differences were identified.
Clinical studies with DuoTrav eye drops (BAK). Adult patients with diagnoses of predominantly primary open angle glaucoma, ocular hypertension or pigmentary glaucoma participated in three randomised, double masked, parallel group multicenter studies (n = 982) to demonstrate the safety and efficacy of DuoTrav Eye Drops. These studies evaluated the IOP lowering effect of DuoTrav Eye Drops dosed once daily (morning) over three months compared to:
monotherapy with its individual components (mean baseline intraocular pressures of 27 to 30 mmHg), travoprost 0.004% dosed once daily (evening) and timolol 0.5% dosed twice daily (contribution of elements; study 1);
concomitant administration of travoprost 0.004% and timolol 0.5% (mean baseline intraocular pressures of 23 to 26 mmHg), both dosed once daily (evening and morning, respectively; study 2). One study also used timolol 0.5% dosed twice daily (study 3).
The primary efficacy parameter for all studies was mean IOP at 8 am, 10 am and 4 pm. The proportion of patients with IOP < 18 mmHg was measured as a secondary efficacy parameter.
Approximately 22% to 37% of the patients included in the studies were treatment naïve patients. All other patients were receiving monotherapy (49% to 57%) with either timolol, a prostaglandin or other medication; two medications (11% to 17%) or three plus medications (2% to 4%).
In the contribution of elements study (study 1), the mean IOP lowering effect of DuoTrav Eye Drops dosed once daily in the morning was 8.7 to 11.5 mmHg, and was 0.4 to 1.8 mmHg greater than Travatan 0.004% dosed once daily in the evening and 1.5 to 2.7 mmHg greater than that of timolol 0.5% dosed twice daily. However, there are no data to show the optimal dose of these agents in combination. In the two concomitant administration studies, the mean IOP reductions of DuoTrav Eye Drops were similar to those achieved by concomitant therapy with Travatan dosed once daily in the evening and timolol dosed once daily in the morning (see Table 1). Differences in mean IOP change from baseline at 10 am and 4 pm were approximately 1 mmHg, favouring concomitant therapy. No differences were observed at 8 am. When DuoTrav Eye Drops was compared to concomitant therapy (study 2 and study 3), noninferiority was not demonstrated at all time points. However, pooled analyses revealed noninferiority. Six month extension data were consistent with previous findings in the individual studies.
DuoTrav Eye Drops yielded IOP < 18 mmHg at one or more timepoints at all visits throughout the entire 3 month period for 50% of patients in the contribution of elements study, and for 74% of patients in a pooled analysis of the concomitant administration studies.
Double masked extensions of the three studies mentioned above were conducted for up to an additional three months. The IOP lowering effect of DuoTrav Eye Drops was maintained during this period.
A separate dosing study (morning or evening) confirmed that the IOP lowering efficacy of once daily DuoTrav Eye Drops is independent of the time of dosing.
A similar safety profile was observed comparing therapy with DuoTrav Eye Drops to concomitant therapy with the individual components (travoprost 0.004% + timolol 0.5%) or to monotherapy with each component (travoprost 0.004%; timolol 0.5%).

5.2 Pharmacokinetic Properties

Absorption.

Travoprost and timolol are absorbed through the cornea. Travoprost undergoes rapid ester hydrolysis in the cornea to the active free acid. Following topical ocular administration of DuoTrav Eye Drops (Polyquad preserved) once daily in healthy subjects (n = 22) for 5 days, the travoprost free acid was not quantifiable in plasma samples from the majority of subjects (94.4%) and generally was not detectable in samples one hour after dosing. In those subjects in whom travoprost free acid was measurable (≥ 0.01 nanogram/mL, the assay limit of quantitation), plasma concentration ranged from 0.01 to 0.03 nanogram/mL. The mean peak timolol steady-state concentration was 1.34 nanogram/mL after once daily administration of DuoTrav Eye Drops (Polyquad preserved). Timolol Tmax was approximately 0.69 hours after dosing.

Distribution.

Travoprost free acid can be measured in the aqueous humour during the first few hours in animals and in human plasma only during the first hour after topical ocular administration of DuoTrav Eye Drops. Timolol can be measured in human aqueous humour after topical ocular administration of timolol and in plasma for up to 12 hours after topical ocular administration of DuoTrav Eye Drops.

Metabolism.

The metabolic pathways of the travoprost free acid parallel those of endogenous PGF2α and are characterised by reduction of the 13-14 double bond, oxidation of the 15-hydroxyl group and β-oxidation of the carboxylic acid chain. The plasma elimination of the free acid was rapid with a mean apparent t1/2 of approximately 45 minutes. There was no difference in plasma concentrations between days 1 and 3, indicating lack of drug accumulation following repeated administration of DuoTrav Eye Drops. Timolol is extensively metabolised in the liver. The apparent terminal elimination t1/2 of timolol in plasma was approximately 4 hours after topical ocular administration of DuoTrav Eye Drops.

Excretion.

Travoprost free acid and its metabolites are mainly excreted by the kidneys. In humans, less than 2% of a topical ocular dose of travoprost was recovered in urine as free acid. Timolol and its metabolites are primarily excreted by the kidneys. Approximately 20% of a timolol dose is excreted in the urine unchanged and the remainder excreted in urine as metabolites.

5.3 Preclinical Safety Data

Genotoxicity.

Mutagenicity studies with DuoTrav Eye Drops have not been conducted.

Travoprost.

Travoprost did not cause gene mutation in bacteria or chromosomal aberrations in bone marrow cells of mice and rats. A slight increase in mutation frequency was observed in one of two mouse lymphoma L5178Y assays. Weight of evidence indicates that travoprost is unlikely to pose a genotoxic risk from clinical use.

Timolol.

In vitro and in vivo studies with timolol maleate did not reveal a mutagenic potential.

Carcinogenicity.

Carcinogenicity studies with DuoTrav Eye Drops have not been conducted.

Travoprost.

Long-term studies in mice and rats at subcutaneous doses up to 100 microgram/kg/day did not provide any evidence of carcinogenic potential. These doses correspond to exposure levels over 200 times human exposure at the maximum recommended human ophthalmic dose (MRHOD), based on plasma active drug levels.

Timolol.

No evidence of carcinogenicity was observed with timolol maleate at oral doses up to 100 mg/kg/day in rats and 50 mg/kg/day in mice. However, there was a statistically significant increase in the incidence of adrenal phaeochromocytomas in male rats administered 300 mg/kg/day. In female mice, statistically significant increases in the incidence of benign and malignant pulmonary tumours, benign uterine polyps and mammary carcinomas were found at 500 mg/kg/day. The increased incidence of mammary tumours was considered to be attributed to a species elevation in serum prolactin.

6 Pharmaceutical Particulars

6.1 List of Excipients

Ethoxylated hydrogenated castor oil, propylene glycol, boric acid, mannitol, sodium chloride, sodium hydroxide and/or hydrochloric acid and purified water. The solution is preserved with polyquaternium-1.

6.2 Incompatibilities

Incompatibilities were either not assessed or not identified as part of the registration of this medicine.

6.3 Shelf Life

In Australia, information on the shelf life can be found on the public summary of the Australian Register of Therapeutic Goods (ARTG). The expiry date can be found on the packaging.

6.4 Special Precautions for Storage

Store below 25°C. Discard four weeks after opening.

6.5 Nature and Contents of Container

DuoTrav Eye Drops: 2.5 mL bottle with or without pouch.

6.6 Special Precautions for Disposal

In Australia, any unused medicine or waste material should be disposed of in accordance with local requirements.

6.7 Physicochemical Properties

Travoprost is a clear to slightly opalescent, colourless to yellow oil. Travoprost is practically insoluble in water (approximately 44 ppm).
Timolol maleate is a white to off white, crystalline powder which is soluble in water, alcohol and practically insoluble in ether.

Chemical structure.

Travoprost.


Molecular weight: 500.56.
Empirical formula: C26H35F3O6.
Chemical name: (5Z,13E)-(9S,11R,15R)-9,11,15-trihydroxy-16-(m trifluoromethylphenoxy) 17,18,19,20-tetranor-5,13-prostadienoic acid, isopropyl ester.

Timolol maleate.


Molecular weight: 432.50.
Empirical formula: C13H24N4O3S.C4H4O4.
Chemical name: (S)-1-(tert-butylamino)-3-[(4-morpholino-1,2,5-thiadiazol-3-yl) oxy]-2 propanol maleate (1:1) (salt).

CAS number.

Travoprost.

157283-68-6.

Timolol maleate.

26921-17-5.

7 Medicine Schedule (Poisons Standard)

Prescription Only Medicine (Schedule 4).

Summary Table of Changes